| Literature DB >> 35982910 |
Haoming Luo1,2, Mingxing Li1,2, Fang Wang1,2, Yifei Yang1,2, Qin Wang1,2, Yueshui Zhao1,2,3, Fukuan Du1,2,3, Yu Chen1,2,3, Jing Shen1,2,3, Qianyun Zhao1,2, Jiuping Zeng1,2, Shengpeng Wang4, Meijuan Chen1, Xiaobing Li1, Wanping Li1, Yuhong Sun1, Li Gu1, Qinglian Wen5, Zhangang Xiao5,1, Xu Wu1,4.
Abstract
Intestinal stem cells (ISCs) play an important role in maintaining intestinal homeostasis via promoting a healthy gut barrier. Within the stem cell niche, gut microbiota linking the crosstalk of dietary influence and host response has been identified as a key regulator of ISCs. Emerging insights from recent research reveal that ISC and gut microbiota interplay regulates epithelial self-renewal. This article reviews the recent knowledge on the key role of ISC in their local environment (stem cell niche) associating with gut microbiota and their metabolites as well as the signaling pathways. The current progress of intestinal organoid culture is further summarized. Subsequently, the key challenges and future directions are discussed. © The author(s).Entities:
Keywords: Gut microbiota; Intestinal barrier; Intestinal homeostasis; Intestinal stem cell; Signaling pathway
Mesh:
Year: 2022 PMID: 35982910 PMCID: PMC9379405 DOI: 10.7150/ijbs.72600
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 10.750
Figure 1The components in intestinal structure for maintaining intestinal barrier. The intestinal barrier consists of two layers: the outer layer consists of the intestinal microbiota (including bacteria, viruses, and pathogens), the mucus layer and the ECs, working together to form a physical barrier against infection. The mucus layer contains sIgA produced by Paneth cells and mucins produced by goblet cells, in addition to intercellular TJs. The inner layer provides a chemical barrier to prevent the spread of bacteria into the host tissue. The GALT is an important immune system in the gut and is composed of the Peyer's patches, the interdigitating lymphocytes, plasma cells and lymphocytes presented in the lamina propria, and mesenteric lymph nodes. All of these are closely linked to the blood circulation in the body.
Figure 2ISC niche and its differentiation. The regulation of the activity of ISCs is dependent on the stem cell niche, including surrounding stromal cells and signaling molecules. The intestinal epithelium is made up of one type of absorptive cell and four types of secretory cells. Transit-amplifying (TA) cells act as direct descendants of ISCs, including secretory and absorptive progenitors, which can give rise to stem-like cells following stem cell injury. Secretory progenitors are differentiated into Paneth cells, goblet cells, tuft cells, and enteroendocrine cells, while absorptive progenitors are differentiated into enterocytes.
Alteration of gut microbiota in diseases and the associated mechanisms.
| Disease | Characteristics or Alterations | Effects | References |
|---|---|---|---|
| Healthy subject | High gut bacterial diversity and microbial growth rates; | Related to gene, environmental and individual differences | |
| Obesity | Decreased abundance: | Diet/ high BMI-related | |
| Type 2 diabetes (T2D) | Decreased abundance: | Functional alterations in the metagenomes as causes or progression factor | |
| Atherosclerotic cardiovascular disease (ACVD) | Decreased abundance: | Unknown |
|
| Cardio-metabolic diseases (CMD) | Decreased abundance: | Their metabolites blocking NF-κB activation and IL-8 secretion |
|
| Chronic heart failure (CHF) | Decreased abundance: | Associated with altered fecal and plasma metabolic patterns |
|
| Non-alcoholic fatty liver disease (NAFLD) | Decreased abundance: | Excess endogenous alcohol production; An elevated level of proinflammatory cytokines | |
| Non-alcoholic steatohepatitis (NASH) | Decreased abundance: | Excess endogenous alcohol production; Higher fecal concentrations of 2-butanone and 4-methyl-2-pentanone that cause hepatocellular toxicity | |
| Liver cirrhosis | Elevated abundance: Proteobacteria; Fusobacteria | An increase of microbial haem biosynthesis and phosphotransferase systems |
|
| Malnutrition, Severe acute malnutrition (SAM) | Decreased abundance: | Related with not breastfeeding and unhealthy diet |
|
Figure 3The interplay between gut microbes/ microbial metabolites/ dietary factors and ISCs. The intestinal microbiota, gut microbial metabolites (including SCFAs, SBAs, tryptophan metabolites, etc.) and dietary influences (including HFD, polysaccharides, etc.) affect the development of the intestinal mucosa mainly through Wnt/β-catenin, JNK, JAK-STAT and other signaling molecules to promote/ inhibit ISC proliferation.
The effects of the gut microbiota/ its metabolites on ISCs in different intestinal states.
| Gut microbiota/ metabolites | Model | Effects on ISCs | Mechanisms | References |
|---|---|---|---|---|
| Preterm infant gut microbiota | Humanized microbiome gnotobiotic mouse model | Promoting cell proliferation | Upregulating the expression of Cryptdin 5, Muc3 and Lyz1 |
|
| Lactic acid producing bacteria | Normal mouse/ Drosophila | Promoting proliferation | Stimulating the Wnt/β-catenin pathway through GPR81; | |
| Gut damage in mice caused by radiation and methotrexate; Gut damage in drosophila ( | Promoting proliferation and enhancing regeneration | GPR81 activation and downstream regulation on Wnt3; | ||
|
| Normal mouse intestinal organoid | Promoting proliferation | Stimulating the Wnt/β-catenin pathway through increase in R-spondins |
|
| TNF-induced intestinal organoid damage; C. rodentium-induced intestinal inflammation in mice | Promoting proliferation and differentiation | Activating the Wnt/β-catenin pathway and upregulating Wnt3 and Lrp5 expression |
| |
|
| Promoting proliferation and division | Initiating the JAK-STAT signaling |
| |
|
| DSS-induced mouse colitis model | Protecting ISCs from inflammatory injury and inducing proliferation | Rebalancing the intestinal flora |
|
| SCFAs (acetate, butyrate, propionate) | Crypt culture | Butyrate: Promoting proliferation | Unknown |
|
| Mice treated with vancomycin; | Valproic acid, Acetate, Propionate, and Butyrate: Promoting proliferation | Notch activating; | ||
| Primary colonic ISCs | Butyrate: Inhibitory effect | Foxo3-dependent | ||
| Hydrochloric acid induced rat epithelial injury model | Butyrate: No effect | Unknown |
| |
| Lactate (SCFAs intermediate metabolites) | Normal mouse; Mouse small intestine organoid; Gut damage caused by radiation or methotrexate | Promoting proliferation and regeneration | GPR81 stimulates of the Wnt/β-catenin signal pathway |
|
| Succinate (SCFAs intermediate metabolites) | Normal rat | Inhibiting proliferation | Unknown |
|
| Tryptophan metabolite | AhR-/- mouse | Indoleacetic acid (IAA): Inhibiting proliferation | Suppresses β-catenin signals through AhR |
|
| AhR-/- mouse, VillinCreAhrfl/fl mouse; | Indole-3-carbinol (I3C): Inhibiting proliferation | Activating AhR | ||
| DSS-induced mouse IBD model | Indoleacrylic acid (IA): Promoting differentiation | Activates AhR to elevate expression of Ki67 |
| |
| TNF-α-induced intestinal organoid injury; | Indolealdehyde (IAld): Promoting differentiation | Induction of IL-22 | ||
| Secondary bile acids: lithocholic acid (LCA), deoxycholic acid (DCA) | Human colon cancer cell model; Rat small intestinal crypt cells | Promoting proliferation at low dose, and inhibition at high dose | Promotion: Possible involvement of Wnt/β-catenin signaling | |
| Polyamines | Rat small intestinal crypt cells; | Promoting proliferation | Inducing TGF-βRI; |
Figure 4A proposed epigenetic configuration involving distinct metabolic pathways that contributes to “butyrate paradox”. Figure reused with permission from Ref. 65. Copyright @ 2021 by Pooja S. Salvi and Robert A. Cowles.
Figure 5The Notch signaling pathway in ISC regulation. The Notch signaling receptor is a single transmembrane protein with functional extracellular (NECD), transmembrane (TM) and intracellular (NICD) structural domains. Delta and Senate families are ligands for Notch. First, the Notch receptor is sheared and glycosylated within the Golgi of the recipient cell, followed by S1 cleavage with TM-NICD. Endosomes transfer processed receptors to the plasma membrane, where it binds to the ligand via Deltex regulation and NUMB inhibition. Secondly, TACE (TNF-ADAM: metalloproteinase convertase) shears NECD away from the TM-NICD structural domain when it binds to the ligand (S2 cleavage). Lastly, NECD-linked ligands form a complex. In signal-receiving cells, NICD is released from the TM by-secretase (S3 cleavage), resulting in nuclear translocation, binding to the CSL transcription factor complex and allowing transcription of traditional Notch target genes.
Figure 6The canonical Wnt/β-catenin signaling pathway in ISC regulation. A ligand for the canonical Wnt/β-catenin attaches to Frizzled receptors then assembles a complex on the surface of the cell together with LRP5/6. The binding of R-spondin to LGR5/6 inhibits the frizzled receptor's activity by ubiquitinating ZNRF3 and RNF43. When the Wnt receptor complex is activated, GSK-3β is dissociated from APC/Axin/GSK-3β. Dvl is activated by sequential phosphorylation, polymerization and polyubiquitination in response to PAR-1 and is inhibited by CYLD and NaKed. Stable β-catenin enters the nucleus through Rac1, contacts LEF/TCF, displaces co-repressors, then recruits co-activators in Wnt target genes. On the other hand, TGF-β/BMP regulates NLK into the nucleus through TAK1 to inhibit β-catenin expression. Without Wnt signaling, β-catenin acts as a transduction co-regulatory molecule and an intercellular adhesion junction protein, which is phosphorylated by CK1α and the APC/Axin/GSK-3β complex, resulting in ubiquitination and degradation by the proteasome via the β-TrCP/Skp pathway. In addition, β-catenin works in concert with several different transcription factors to control specific targets.
Figure 7The BMP signaling pathway in ISC regulation. BMP signaling contains a complex formation of different type 1 and type 2 receptors for serine/threonine kinase activity. Noggin and Gremlin are extracellular inhibitors of BMP. After ligand binding to the receptor and entry into the cell, firstly, the downstream molecules of BMP signaling, SMAD1/5/8, are phosphorylated by ALK2/3/6 and ALK1, and then BMP signaling is highly activated by the phosphorylated SMAD1/5/8. Of these, SMAD6/7, particularly SMAD6, is involved in inhibiting phosphorylation and signaling, which inhibits ALK3/6-mediated signaling. Finally, phosphorylated SMAD1/5/8 aggregates with Smad4 and continues to signal, accumulating in the nucleus and regulating target gene transcription.